When was Quratis founded?

Quratis was founded in 2016 and raised its 1st funding round 7 years after it was founded.

Where is Quratis located?

Quratis is headquartered in Seoul, South Korea.

How many employees does Quratis have?

As of Jul 01, 2024, the latest employee count at Quratis is 9.

Is Quratis a funded company?

Quratis is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 30, 2023.

When was the latest funding round of Quratis?

Quratis' latest funding was a $***** Seed round on Nov 30, 2023, with participation from 0 investor. Its primary sector is Immunotherapy. In South Korea, the Immunotherapy sector has seen $35.9M in funding in 2026 to date.

Where does Quratis rank among its competitors?

Quratis ranks 22nd amongst 140 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Quratis?

Quratis' top competitors include Emergent BioSolutions, Evofem and Insmed. Among them, Basilea secured the most recent funding round in May, 2026.

Quratis - 2026 Company Profile, Team, Funding & Competitors

Quratis is a seed company based in Seoul (South Korea), founded in 2016. It operates as a Developer of vaccines and cell therapies for treating tuberculosis. Quratis has raised an undisclosed amount in funding. The company has 140 active competitors, including 34 funded and 29 that have exited. Its top competitors include companies like Emergent BioSolutions, Evofem and Insmed.

Company Details

Quratis is developing vaccines and cell therapies for treating tuberculosis. The lead candidates of the company, ID93 ( fusion protein)/GLA-SE (next generation adjuvant) is used for treating tuberculosis. It has completed Phase I studies. It boosts the immune reaction induced by BCG.

Website: quratis.com/ko/
Email ID: *****@quratis.com
Phone Number: +82 **********

Key Metrics

Founded Year

2016

Location

Seoul, South Korea

Stage

Seed

Latest Funding Round

Seed, Nov 30, 2023, $*****

Investors

STIC Ventures & 4 more

Ranked

22^nd among 140 active competitors

Employee Count

9 as on Jul 01, 2024

Similar Companies

Emergent BioSolutions & 181 more

View Quratis' full profile

Quratis has raised funding over 1 round. Quratis has 5 institutional investors.

Here is the list of recent funding rounds of Quratis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 30, 2023	5330975	Seed	8936285	8110994	6003867	8157617

Access funding benchmarks and valuations. Sign up today!

View details of Quratis's funding rounds and investors

Quratis' employee count trend

Quratis has 9 employees as of Jul 24. Here is Quratis's employee count trend over the years:

Uncover Quratis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quratis include Emergent BioSolutions, Evofem and Insmed. Here is the list of Top 10 competitors of Quratis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Emergent BioSolutions 1998, Gaithersburg (United States), Public	Developer of vaccines primarily for virus infections	-	Advent Life Sciences, NISA & 12 others	69/100
2nd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	66/100
3rd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
4th	Kineta 2008, Seattle (United States), Acquired	Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases	$127M	Cheongbo Industrial, Pfizer & 10 others	59/100
5th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
6th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
7th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	57/100
8th	Immunophotonics 2008, St. Louis (United States), Series B	Developer of therapeutics for the treatment of interventional immuno-oncology	$38.3M	Zubizoom, ROVAQ Ventures & 12 others	57/100
9th	Eubiologics 2012, Seoul (South Korea), Public	Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems.	$7.5M	IMM Investment, Global Health Investment Fund ... & 8 others	56/100
10th	Minervax 2010, Hellerup (Denmark), Series C	Developer of vaccines against life-threatening infections in newborns	$197M	EQT, Sanofi Ventures & 14 others	54/100
22nd	Quratis 2016, Seoul (South Korea), Seed	Developer of vaccines and cell therapies for treating tuberculosis	-	STIC Ventures, DA Value Investment & 3 others	44/100